Five new first-in-human clinical research projects have been acquired by Malaysia
Health Minister Datuk Seri Dr Dzulkefly Ahmad announced that Malaysia has received the maximum number of First-in-Human (FIH) clinical research ever attained with the introduction of five new FIH trials through Clinical Research Malaysia (CRM).
According to him, the accomplishment serves to bolster Malaysia’s status as a premier clinical research center in the region and to demonstrate the country’s capacity, quality, and standards in the management of clinical research.
After officiating CRM’s office at the Kuala Lumpur Hospital yesterday, Dzulkefly, who is also the chairman of CRM’s Board of Directors, stated, “After reviewing CRM’s clinical research performance and the country’s achievements, I must highlight that Malaysia has received five new First-in-Human (FIH) studies.”
In a statement released today by CRM, Dzulkefly stated that Malaysia recorded 239 sponsored clinical research projects from January to November 2024, which contributed over RM330 million to the Gross National Income.
Since 2012, the sector has generated almost RM1.5 billion cumulatively.
According to Dzulkefly, cancer accounted for nearly one-third of this research, with a focus on providing patients in Malaysia with innovative and high-quality therapies.
Furthermore, CRM announced the establishment of its new operational site office at HKL, which serves to fortify CRM’s network of satellite entities.
The network now includes site offices at the Sarawak General Hospital and the Raja Permaisuri Bainun Hospital in Ipoh, in addition to CRM’s Centre of Excellence, established earlier this year.
At the same occasion, Dr. Dzulkefly observed the signing of a memorandum of understanding (MoU) between CRM and BeiGene, a global oncology company that is based on science.
The collaboration’s objective is to fortify Malaysia’s clinical research ecosystem, with a particular emphasis on the advancement of clinical research activities and the enhancement of capacity development.